{"doi":"10.1016/j.amjmed.2023.02.019","title":"New Drugs Approved in 2022","abstract":null,"journal":"The American Journal of Medicine","year":2023,"id":605278,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1553319,"name":"Hesham Elmariah","orcid":null,"position":1,"is_corresponding":false},{"id":1553320,"name":"Rhonda M. Cooper-DeHoff","orcid":null,"position":2,"is_corresponding":false},{"id":1553318,"name":"Alex M. Ebied","orcid":"0000-0003-1133-413X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"New Drugs Approved in 2022","abstract":"In 2022, the US Food and Drug Administration (FDA) approved 37 novel drugs. Twenty-four of the 37 (65%) novel drug approvals were reviewed and approved through an expedited review pathway and 20 of the 37 (54%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the FDA in 2022.","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36889492","pmcid":null,"openalex_id":"https://openalex.org/W4323315502","authors":[],"funders":[],"total_grants":0,"fwci":1.3035,"citation_percentile":0.80823334,"influential_citations":0,"citation_trend":[{"year":2023,"count":2},{"year":2024,"count":4}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0002934323001535?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0002934323001535?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.amjmed.2023.02.019","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36889492","host_type":"repository"}],"fields_of_study":["Genomics and Rare Diseases","Cancer-related gene regulation","PI3K/AKT/mTOR signaling in cancer","United States","Humans","Pharmaceutical Preparations","Drug Approval","United States Food and Drug Administration"],"mesh_terms":["Pharmaceutical Preparations","Humans","United States","United States Food and Drug Administration","Drug Approval"],"keywords":["Medicine","Food and drug administration","Drug approval","Drug","Approved drug","Pharmacology","Off-label use","Intensive care medicine","Fast Track","Fda","Novel Drugs","Accelerated Approval","Priority Review"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T02:04:53.930312Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}